despit
random
clinic
trial
rct
multipl
potenti
therapi
intervent
acut
respiratori
distress
syndrom
ard
reduc
mortal
minim
ventilatorinduc
lung
injuri
translat
failur
may
number
explan
firstli
ard
syndrom
intervent
trial
ard
gener
includ
heterogen
patient
group
wide
spectrum
diseas
etiolog
diseas
sever
second
deficit
exist
understand
key
aspect
pathogenesi
ard
notwithstand
challeng
number
promis
therapi
current
investig
ard
offer
hope
futur
aspirin
platelet
import
ard
pathogenesi
preclin
studi
aspirin
reduc
thromboxan
pselectin
plateletderiv
chemokin
eg
product
reduc
plateletneutrophil
aggreg
neutrophil
extracellular
trap
enhanc
antiinflammatori
lipid
mediat
aspirin
reduc
risk
develop
ard
critic
ill
patient
clinic
studi
aspirin
human
volunt
undergo
endotoxin
inhal
arena
rct
aspirin
ard
prevent
ongo
tabl
hmg
coareductas
inhibitor
statin
exert
divers
pleiotrop
effect
beyond
pharmacolog
effect
cholesterol
reduct
includ
antiinflammatori
endotheli
protect
effect
result
preclin
observ
studi
support
potenti
role
statin
ard
simvastatin
improv
pulmonari
system
organ
function
phase
rct
ard
two
larger
phase
trial
statin
therapi
carri
irelanduk
usa
respect
demonstr
benefit
rosuvastatin
hydrophil
statin
improv
clinic
outcom
sepsisassoci
ard
may
increas
hepat
renal
dysfunct
lipophil
statin
simvastatin
worsen
hepat
renal
function
nonsignificantli
reduc
mortal
increas
number
ventilatorfre
day
vfd
primari
outcom
definit
larg
trial
simvastatin
power
mortal
primari
outcom
may
warrant
activ
coagul
play
key
role
pathogenesi
ard
result
alveolar
fibrin
deposit
impair
ga
exchang
preclin
studi
heparin
found
reduc
alveolar
fibrin
deposit
exert
antiinflammatori
effect
one
small
rct
heparin
decreas
number
vfd
patient
risk
ard
studi
investig
efficaci
nebul
heparin
patient
risk
ard
tabl
underway
interferon
beta
ifnb
increas
endotheli
express
ratelimit
enzym
convers
adenosin
monophosph
adenosin
turn
bind
pulmonari
receptor
exert
multipl
protect
effect
preclin
model
recent
openlabel
doseescal
studi
two
ard
patient
treat
lg
per
day
die
day
compar
mortal
parallel
control
group
although
studi
random
blind
baselin
differ
treat
control
cohort
investig
ifnb
ard
warrant
tumor
necrosi
factor
receptor
blockad
tumor
necrosi
factor
tnf
exert
effect
bind
one
two
tnf
receptor
design
tnfactiv
proinflammatori
pathway
program
cell
death
pathway
result
tissu
injuri
larg
mediat
signal
play
role
tissu
repair
angiogenesi
promis
preclin
data
support
efficaci
monoclon
antibodi
one
studi
inhal
antibodi
decreas
pulmonari
inflamm
induc
endotoxin
healthi
volunt
earli
phase
studi
ard
patient
await
angiotensin
convert
enzym
angiotensinconvert
enzym
ace
cleav
angiotensini
gener
angiotensinii
caus
vasoconstrict
inflamm
increas
vascular
permeabl
via
type
type
receptor
homolog
ace
cleav
singl
residu
angii
gener
block
mani
action
imai
et
al
found
ace
angii
function
lung
injurypromot
factor
wherea
protect
lung
injuri
receptor
sever
acut
respiratori
syndromecoronaviru
sarscov
sarscov
induc
downregul
import
step
develop
sever
lung
failur
addit
mortal
increas
patient
ard
ace
dd
phenotyp
result
greater
ace
activ
human
phase
iii
clinic
trial
recombin
human
therapi
patient
earli
ard
progress
tabl
adrenomedullin
adrenomedullin
endogen
amino
acid
peptid
belong
calcitonin
generel
peptid
famili
express
multipl
tissu
includ
endotheli
cell
play
crucial
role
endotheli
barrier
integr
act
via
bind
calcitonin
receptorlik
receptor
therebi
rais
intracellular
camp
level
endotheli
cell
reduc
myosin
light
chain
mlc
phosphoryl
thu
may
prevent
endotheli
contract
intercellular
gap
format
express
upregul
inflammatori
diseas
includ
ard
sepsi
endogen
may
contribut
protect
vascular
function
inflamm
therapi
reduc
pulmonari
permeabl
injuri
decreas
inflamm
experiment
ard
sepsi
committe
orphan
medicin
product
european
medicin
agenc
ema
recent
recommend
orphan
drug
treatment
ard
clinic
trial
plan
stage
keratinocyt
growth
factor
kgf
fibroblast
growth
factor
express
predominantli
mesenchym
cell
receptor
kgfr
express
epitheli
cell
macrophag
result
preclin
studi
suggest
intratrach
kgf
reduc
lung
injuri
induc
hyperoxia
ventilatorinduc
lung
injuri
bacteri
pneumonia
recent
studi
kgf
treatment
palifermin
increas
marker
type
ii
alveolar
epitheli
cell
prolifer
increas
alveolar
concentr
repar
proteas
antiinflammatori
cytokin
follow
endotoxin
inhal
volunt
phase
ii
clinic
trial
palifermin
ard
recent
conclud
result
await
tabl
mesenchym
stemstrom
cell
mesenchym
stemstrom
cell
msc
regul
innat
adapt
immun
system
modul
macrophag
phenotyp
inhibit
product
inflammatori
cytokin
activ
cell
stimul
gener
regulatori
cell
potenti
reduc
proinflammatori
cytokin
ard
msc
directli
attenu
bacteri
sepsi
commonest
sever
caus
ard
enhanc
macrophag
phagocytosi
increas
antimicrobi
peptid
secret
therebi
increas
bacteri
clearanc
msc
also
repair
injur
lung
follow
ventilationinduc
lung
injuri
via
paracrin
mechan
recent
pilot
studi
msc
therapi
ard
demonstr
advers
effect
phase
openlabel
doseescal
multicent
clinic
trial
allogen
bmmsc
patient
moder
sever
ard
underway
usa
tabl
although
mani
fail
therapi
date
new
therapi
base
improv
understand
mechan
implic
develop
ard
emerg
may
provid
treatment
option
near
futur
